Anivance

Drug development solution, Paitent on chips

Based based in Taiwan, Anivance works in health.

Profile

Anivance AI is transforming preclinical research with an end-to-end platform aligned with the U.S. FDA’s 2025 roadmap for New Approach Methodologies (NAMs). By replacing traditional animal testing with scalable, predictive, and ethically sound technologies, we accelerate safer, faster drug development. Our integrated system combines organ-on-chip modeling, high-throughput phenotypic profiling, and predictive AI to deliver actionable insights in oncology, rare diseases, and advanced drug delivery. With 25 patents and partnerships across 50+ physicians and six clinical institutions, Anivance AI is backed by Taiwan’s largest public tech firms and was nominated for the LUSH Prize in Science. We pioneer a “No Animals, No Delays, Just Human Data” vision.

Anivance is positioned in health, a segment that rewards a clear, focused offering.

The company is recorded as being based in Taiwan.

The company is listed at the Plug and Play accelerated startup stage of development.

Website: anivance.io